Drug Design Defect Claims Post-Bartlett
In June 2013, the U.S. Supreme Court in Mutual Pharmaceutical Co. v. Bartlett[1] held that "state law design defect claims that turn on the adequacy of a drug's warnings are preempted...To view the full article, register now.
Already a subscriber? Click here to view full article